Muller Kristen, Jorns Julie M, Tozbikian Gary
Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA.
J Pathol Transl Med. 2022 May;56(3):170-171. doi: 10.4132/jptm.2022.04.25. Epub 2022 May 15.
The 5th edition WHO Classification of Breast Tumours (2019) has introduced changes to our practices. Highlights are presented below, with a focus on modifications to morphological subtype categorization. In addition, we summarize important updates to ER and PR testing made in the 2020 ASCO/CAP guidelines, and briefly discuss PD-L1 and Ki-67 testing in breast cancer.
世界卫生组织《乳腺肿瘤分类》第5版（2019年）对我们的实践带来了变化。以下是要点介绍，重点关注形态学亚型分类的修改。此外，我们总结了2020年美国临床肿瘤学会/美国病理学家学会（ASCO/CAP）指南中对雌激素受体（ER）和孕激素受体（PR）检测的重要更新，并简要讨论了乳腺癌中的程序性死亡受体1配体（PD-L1）和Ki-67检测。
